GO
Loading...

Enter multiple symbols separated by commas

Stocks Teva Pharmaceutical Industries Ltd

More

  • WASHINGTON, July 14- A proposed merger of the two largest U.S. generic drug makers drew fire on Tuesday from Consumers Union and seven other groups, who asked antitrust enforcers to stop Teva Pharmaceutical Industries Ltd's proposal to purchase Mylan NV, saying it would lead to higher prices and more drug shortages. Meanwhile, Mylan has pressed on with a $34...

  • TEL AVIV, July 8- As Israel's biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food chain a raft of upstart life science firms are struggling to climb onto the global ladder. Israel has a burgeoning life science industry comprising around 1,380 mostly very small companies.

  • Your first trade for Wednesday Tuesday, 7 Jul 2015 | 6:14 PM ET

    The "Fast Money" traders give their final trades of the day.

  • M&A close to record in Q2 amid mega deals Tuesday, 30 Jun 2015 | 6:54 AM ET
    mergers

    Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007.

  • NEW YORK/ LONDON, June 29- Mergers and acquisitions worldwide in the second quarter of 2015 almost matched the record set in the second quarter of 2007, according to preliminary Thomson Reuters data, as big companies turned to deals to boost their market share. These include Royal Dutch Shell Plc's $70 billion acquisition of British rival BG Group Plc, cable...

  • TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. Perrigo's shares have been listed on TASE since it acquired Israeli...

  • Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Wednesday, 24 Jun 2015 | 9:07 AM ET

    TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. "Mylan believes that the Israeli market is important to Mylan and the...

  • TEL AVIV, June 23- Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying Perrigo Co, an industry source said. Mylan has offered to acquire Perrigo for $34 billion in an attempt to fend off a bid from Israel's Teva...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The transaction is the latest sign of the hectic pace of...

  • LONDON, June 22- European private equity fund CVC and Singaporean sovereign wealth fund Temasek are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said. Robert Wessman, former CEO of Actavis, founded the New Jersey- based generic drugs firm in 2009.. The transaction is the latest sign of the hectic pace of...

  • NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. The decision, by the U.S. Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's...

  • U.S. appeals court again invalidates Teva MS drug patent Thursday, 18 Jun 2015 | 11:56 AM ET

    NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.

  • June 16- Mylan NV's largest stakeholder, Abbott Laboratories, said it would back Mylan's proposed acquisition of Perrigo Co Plc, potentially helping Mylan fend of interest from Teva Pharmaceutical Industries Ltd. Abbott, which has a 14.5 percent stake in Mylan, said on Tuesday that it supported Mylan's "standalone strategy" and believed acquiring Perrigo...

  • Abbott to vote for Mylan's acquisition of Perrigo Tuesday, 16 Jun 2015 | 9:20 AM ET

    June 16- Abbott Laboratories said it would vote its 14.5 percent stake in Mylan NV in favor of Mylan's proposed acquisition of Perrigo Company Plc. Mylan's latest offer for Perrigo, worth $34.1 billion, is widely seen as an attempt to fend off Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs. Abbott, Mylan's largest shareholder, said...

  • UPDATE 1-Teva switches legal counsel after Mylan challenge Wednesday, 10 Jun 2015 | 12:41 AM ET

    June 9- Teva Pharmaceutical Industries Ltd has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV after a court sided with the latter's bid to seek a preliminary injunction against the previous law firm. Teva is now working with Sullivan& Cromwell LLP as legal counsel in its proposal to acquire Mylan, the...

  • June 5- Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda's weight-loss treatment. Actavis and Teva Pharmaceutical Industries...

  • Early movers: EXPE, LNKD, DIS, GES, HPQ & more Wednesday, 3 Jun 2015 | 7:54 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • These are the best stocks from now to October Tuesday, 2 Jun 2015 | 10:56 AM ET
    Healthcare

    Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.

  • Early movers: MDT, PVH, DG, SHLD, AAPL & more Tuesday, 2 Jun 2015 | 7:48 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • June 1- Mylan NV said Teva Pharmaceutical Industries Ltd, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake. Teva disclosed a 1.35 percent stake in Mylan last week. Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.